NCT01982630View on ClinicalTrials.gov

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

November 7, 2013

Primary Completion Date

October 3, 2014

Study Completion Date

October 3, 2014

Conditions
Diabetes Mellitus
Interventions
DRUG

MK-8521

DRUG

Liraglutide

DRUG

Placebo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01982630 - Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003) | Biotech Hunter | Biotech Hunter